← Back to Trial

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Trial Locations

• Honor Health Research Institute Scottsdale, Arizona, United States
  • Contact: Cierra Spikes · [email protected] (opens in new tab)
• VA Greater LA Healthcare System Los Angeles, California, United States
  • Contact: Janake Wijesuriya · [email protected] (opens in new tab)
• VA Palo Alto Health Care System Palo Alto, California, United States
  • Contact: Pallavi Gautam · 650-493-5000 · [email protected] (opens in new tab)
• Stanford University Medical Center Palo Alto, California, United States
  • Contact: Mikayla Easterling · [email protected] (opens in new tab)
• Sansum Clinic Santa Barbara, California, United States
  • Contact: Jessica Wong · 805-563-5800 · [email protected] (opens in new tab)
• Saint Johns Cancer Institute Santa Monica, California, United States
  • Contact: Joey Dumadag · 310-829-8569 · [email protected] (opens in new tab)
• Rocky Mountain Cancer Centers Denver, Colorado, United States
  • Contact: Jannae Foellmer · 303-385-2000 · [email protected] (opens in new tab)
• Hartford Hospital Hartford, Connecticut, United States
  • Contact: Melanie Manning · [email protected] (opens in new tab)
• Baptist Health South Miami, Florida, United States
  • Contact: Leslie Castaneda · [email protected] (opens in new tab)
• AdventHealth Orlando, Florida, United States
  • Contact: Joseph Guzzo · 407-303-3235 · [email protected] (opens in new tab)
• University Cancer and Blood Center LLC Athens, Georgia, United States
  • Contact: Christen Nicole Cooper Pope · +1 706 353 2990 · [email protected] (opens in new tab)
• Emory University Atlanta, Georgia, United States
  • Contact: Jalpa Patel · +1 404 778 1835 · [email protected] (opens in new tab)
• University of Chicago Chicago, Illinois, United States
  • Contact: Paige Olson · 773-702-4848 · [email protected] (opens in new tab)
• Indiana University Indianapolis, Indiana, United States
  • Contact: Marie Burton · [email protected] (opens in new tab)
• University of Kansas Hospital Kansas City, Kansas, United States
  • Contact: Kelsey Schwensen · [email protected] (opens in new tab)
• East Jefferson Hospital Metairie, Louisiana, United States
  • Contact: Alexandra Lieberman · [email protected] (opens in new tab)
• Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Contact: Michael Bonhomme · 617-632-5136 · [email protected] (opens in new tab)
• Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Contact: Ooviya Sathiyamoorthy · 617-643-9923 · [email protected] (opens in new tab)
• WA Uni School Of Med St Louis, Missouri, United States
  • Contact: Collin Welch · 314-454-8293 · [email protected] (opens in new tab)
• Nebraska Cancer Specialists Omaha, Nebraska, United States
  • Contact: Marlene Bridwell · 402-334-4773 · [email protected] (opens in new tab)
• New Jersey Urology LLC Voorhees Township, New Jersey, United States
  • Contact: Gabriela Mercado · 856-673-1613 · [email protected] (opens in new tab)
• Mount Sinai Hosp Med School New York, New York, United States
  • Contact: Ilda Bander · 212-241-8903 · [email protected] (opens in new tab)
• Associated Med Professionals of NY Syracuse, New York, United States
  • Contact: Nathan Forrest · [email protected] (opens in new tab)
• Montefiore Medical Center The Bronx, New York, United States
  • Contact: Tahrima Chowdhury · 718-920-6642 · [email protected] (opens in new tab)
• Central Ohio Urology Group Gahanna, Ohio, United States
  • Contact: Sarah Faisal · [email protected] (opens in new tab)
• Oregon Urology Institute Springfield, Oregon, United States
  • Contact: Maxim Dimarco · [email protected] (opens in new tab)
• Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
  • Contact: Candice Schewbel · 215-728-3075 · [email protected] (opens in new tab)
• Carolina Urologic Research Center Myrtle Beach, South Carolina, United States
  • Contact: Rebecca Floyd · 843-839-1679 · [email protected] (opens in new tab)
• Texas Oncology Dallas, Texas, United States
  • Contact: Marian Heaven · 512-427-9467 · [email protected] (opens in new tab)
• Urology San Antonio San Antonio, Texas, United States
  • Contact: Sandra Davila · [email protected] (opens in new tab)
• Utah Intermountain Medical Center Murray, Utah, United States
  • Contact: Becky Arroyo · [email protected] (opens in new tab)
• Virginia Cancer Specialists Fairfax, Virginia, United States
  • Contact: Kristi Ben-Barka · [email protected] (opens in new tab)
• Onco Hemato Asso of SW Virginia Roanoke, Virginia, United States
  • Contact: Natasha Holt · 540-774-8660 · [email protected] (opens in new tab)
• Fred Hutchinson Cancer Research Center Seattle, Washington, United States
  • Contact: Brianna Woo · [email protected] (opens in new tab)
• Medical College Of Wisconsin Milwaukee, Wisconsin, United States
  • Contact: Nadia Thomas · [email protected] (opens in new tab)
• Novartis Investigative Site Darlinghurst, New South Wales, Australia
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Herston, Queensland, Australia
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Melbourne, Victoria, Australia
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site São Paulo, São Paulo, Brazil
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site São Paulo, São Paulo, Brazil
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Fuzhou, Fujian, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Wuhan, Hubei, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Wuhan, Hubei, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Nanjing, Jiangsu, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Nanjing, Jiangsu, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Shenyang, Liaoning, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Xian, Shanxi, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Xian, Shanxi, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Chengdu, Sichuan, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Beijing, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Beijing, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Guangzhou, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Shanghai, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Shanghai, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Tianjin, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Tianjin, China
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Hong Kong, Hong Kong
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Beersheba, Israel
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Haifa, Israel
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Jerusalem, Israel
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Petah Tikva, Israel
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Ramat Gan, Israel
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Tel Aviv, Israel
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Kashiwa, Chiba, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Sapporo, Hokkaido, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Kobe, Hyōgo, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Yokohama, Kanagawa, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Chiba, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Fukuoka, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Fukuoka, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Fukuoka, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Fukushima, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Ishikawa, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Kyoto, Japan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Putrajaya, Kuala Lumpur, Malaysia
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Petaling Jaya, Selangor, Malaysia
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Petaling Jaya, Selangor, Malaysia
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Mexico City, Mexico City, Mexico
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Huxquilucan, Mexico
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Singapore, Singapore
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Singapore, Singapore
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Singapore, Singapore
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Seoul, South Korea
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Seoul, South Korea
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Seoul, South Korea
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Seoul, South Korea
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Basel, Switzerland
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Bellinzona, Switzerland
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Bern, Switzerland
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Taipei, Taiwan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Taipei, Taiwan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Taipei, Taiwan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)
• Novartis Investigative Site Taoyuan, Taiwan
  • Contact: Novartis Pharmaceuticals · 1-888-669-6682 · [email protected] (opens in new tab)